Please ensure Javascript is enabled for purposes of website accessibility

Here's Why NuVasive, Inc. Popped Today

By Cory Renauer - Oct 25, 2017 at 4:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The spinal surgery underdog posted some impressive growth abroad.

What happened

Shares of NuVasive, Inc. (NUVA 2.24%), a spinal-surgery device manufacturer, popped as high as 9.8% Wednesday morning before settling back down to an 8.1% gain as of 3:07 p.m. A mixed third-quarter earnings report is fueling hope that the company will shift its recently sluggish growth rate back into high gear.

So what

NuVasive served up a cold dish of 3% total sales growth in the third quarter, but management claims adjusting for storm disruptions would raise that figure to 6%. Although U.S. sales fell 3.5% to $201 million, the company reported an impressive 48.1% surge in sales from its international segment.

Person facing upward sloping arrows drawn on a chalkboard.

Image source: Getty Images.

This was the fourth straight quarter that revenue from NuVasive's international operations rose by 20% or more. At $46.4 million, the segment has become large enough to push the entire company forward even if U.S. sales continue to flounder.

Investors were also pleased with plans to take advantage of the stock's recently depressed price and authorized $100 million in stock buybacks.

Now what

If executed at recent prices, the share buybacks would lower NuVasive's outstanding share count by roughly 3.4%. That will send a larger slice of future profits to shareholders, and some impressive cost-cutting following a major executive suite shake-up should go a long way to raise those profits further.

In the first nine months of the year, sales, marketing, and administrative expenses ate into 53% of total sales. A year ago that figure was 57%, and it's falling fast. In fact, sales, marketing, and administrative expenses actually fell 4.6% during the latest quarter compared to the same period a year ago.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NuVasive, Inc. Stock Quote
NuVasive, Inc.
$50.26 (2.24%) $1.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.